REQUIP XL Rx
Generic Name and Formulations:
Ropinirole (as HCl) 2mg, 4mg, 6mg, 8mg, 12mg; ext-rel tabs.
Indications for REQUIP XL:
Swallow whole. Initially 2mg once daily for 1–2 weeks, then increase by 2mg/day at ≥1-week intervals up to max 24mg/day (for advanced disease: usually up to max 8mg/day; early disease: usually up to max 12mg/day). ESRD on dialysis: initially 2mg once daily; max 18mg/day. Switching from immediate-release ropinirole: give initial dose to closely match total daily dose of immediate-release form. Withdraw gradually over 7 days.
See full labeling. Consider discontinuing if excessive daytime sleepiness or if sudden onset of sleep during daily activities occurs. Monitor for drowsiness or sleepiness, and for orthostatic hypotension. Dyskinesia. Sleep disorders. Severe renal or hepatic impairment. Significant cardiovascular disease; monitor for hypertension and changes in heart rate. Psychotic disorders. Urges/compulsive behaviors. Monitor for melanoma; perform periodic skin exams. Fibrotic complications. Avoid abrupt cessation. Elderly. Pregnancy. Nursing mothers.
May potentiate dopaminergic effects (eg, dyskinesia) with levodopa; consider reducing dose of levodopa. Additive CNS effects when concomitant alcohol, other CNS depressants (eg, benzodiazepines, antipsychotics, antidepressants). May be potentiated by CYP1A2 inhibitors (eg, ciprofloxacin). May be antagonized by CYP1A2 inducers (eg, cigarette smoking) or dopamine antagonists (eg, phenothiazines, butyrophenones, metoclopramide). Adjust ropinirole dose if estrogens are added or discontinued.
Dopamine agonist (non-ergot).
Early parkinsonism (without levodopa): nausea, somnolence (including sudden sleep onset), dizziness, syncope, asthenia, infection, edema, vomiting, dyspepsia, hypertension, headache, abdominal pain/discomfort, constipation. Advanced disease (with levodopa): also dyskinesia, confusion, hallucinations (esp. in elderly), sweating. Both: withdrawal-emergent hyperpyrexia and confusion.
Tabs—100; XL tabs—30
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy